Postmenopausal hormone therapy exceeding ten years may protect from dementia
Postmenopausal estrogen-based hormone therapy lasting longer than ten years was associated with a decreased risk of Alzheimer's disease in a large study. The study explored the association between postmenopausal hormone replacement therapy, Alzheimer's disease, dementia and cognition in two nation-wide case-control studies and two longitudinal cohort studies. The largest study comprised approximately 230,000 Finnish women and the follow-up time in different studies was up to 20 years.
DISCUSSION: PET can evaluate amyloid expansion from cortex to subcortex. Using striatal signal as a marker of advanced amyloidosis may increase predictive power in Alzheimer's dementia research. PMID: 29792874 [PubMed - as supplied by publisher]
DISCUSSION: GBA variants are of great clinical relevance for the development of dementia in Parkinson's disease, especially due to the relatively higher frequency of these alleles compared with other risk alleles. PMID: 29792872 [PubMed - as supplied by publisher]
DISCUSSION: White matter hyperintensities are associated with an increased risk of all-dementia and Alzheimer's disease in the general population. However, studies are warranted to further determine the role of markers of cerebral small vessel disease in dementia. PMID: 29792871 [PubMed - as supplied by publisher]
DEMENTIA is a term used to describe different types of brain degeneration. The most common type of dementia is Alzheimer ’s Disease, although vascular dementia and dementia with lewy bodies are also types. Symptoms of dementia include leaving items in the wrong place and memory loss. New research has provided hope for diagnosing dementia early, by finding that people with more yellow spots in their eye are more like ly to have the condition.
Conclusions—Genetic variants within the VCAN gene may play a role in the mechanisms underlying microstructural integrity of the white matter in the brain measured as FA and MD. Mechanisms underlying white matter alterations are shared with cerebrovascular disease, and inherited differences in white matter microstructure impact on Alzheimer disease and major depressive disorder.
Discussion Although Aβ did not differ by sex, cognitive decline was greater in females with higher Aβ. Our findings suggest that sex may play a modifying role on risk of Alzheimer's disease–related cognitive decline.
In a recent paper, researchers provided evidence to suggest that the risk factors associated with cardiovascular decline with age interact with amyloid-β in the brain to accelerate cognitive decline. Having more of both produces a worse prognosis, which is not all that surprising. This is the case in many areas of aging and age-related disease: forms of damage and dysfunction interact with one another, making consequences worse than would be the case if they were independent of one another. This is one of the reasons why aging is an accelerating process, starting off slow and picking up pace ever more rapidly as the d...
Alzheimer’s disease now affects approximately 5.5 million Americans, and it is estimated that 16 million people will be living with the disease by the year 2050. To put this in perspective, while deaths from heart disease have decreased by 14 percent since 2000, deaths from Alzheimer’s disease have increased by 89%. It is interesting to note that 35 percent of caregivers (family and friends) of Alzheimer’s or other dementia patients report that their own health has declined compared to 19 percent of caregivers of older people with no dementia. This illness can cause intense suffering not only for those w...
CONCLUSIONS: The prevalence and incidence of dementia increase exponentially from the age of 65 onwards. As a consequence of the progressive ageing of the population and the increase in life expectancy, the number of cases of dementia will rise in the coming decades. Recent studies point to a slight drop in the accumulated risk of dementia adjusted by age groups and sex over the last few decades in some countries. It is possible that by means of primary prevention strategies implemented upon the known risk factors for dementia the burden of dementia on public health will diminish in the future. PMID: 29790571 [PubMed - in process]
CONCLUSIONS: Further studies using biomarker-underpinned diagnoses are warranted to shed more light on the potential diagnostic utility of BACE1 activity as AD biomarker candidate in MCI. PMID: 29788013 [PubMed - as supplied by publisher]